Tumor Angiogenesis Induced by Granulocyte Chemotactic Protein-2 as a Countercurrent Principle

Els Van Coillie,* Ilse Van Aelst,* Anja Wuyts,* Roeland Vercauteren,* Rita Devos,† Chris De Wolf-Peeters,† Jo Van Damme,* and Ghislain Opdenakker*

From the Laboratory of Molecular Immunology,* Rega Institute for Medical Research, and the Laboratory of Morphology and Molecular Pathology,† University of Leuven, Leuven, Belgium

Chemokine production by tumors is a well-known phenomenon, but its role in tumor biology remains debatable. Although intratumoral injection of granulocyte chemotactic protein-2 (GCP-2) had no effect on tumor parameters, needle-free stable expression of the chemokine resulted in enhanced tumor growth. It is shown here that tumors that express a potent form of GCP-2 induce a strong influx and activation of tumor-associated neutrophils. The production of GCP-2 leads to intratumoral expression of gelatinase B and advantage for tumor growth by increased angiogenesis. These results are in line with the countercurrent principle of chemokine action and support the notion that paraneoplastic expression of ELR-positive CXC chemokines has to be blocked rather than stimulated in cancer therapy. (Am J Pathol 2001, 159:1405–1414)

Chemokines have been associated with tumor biology for a long time. In fact, many chemokines have first been purified from tumor cells.1–5 The production of chemokines by tumor cells may be a paraneoplastic coincidence and either help the host to eliminate the tumor by immunosurveillance mechanisms6 or give an advantage to cancer progression. The latter is called the countercurrent principle of chemokine action and support the notion that paraneoplastic expression of ELR-positive CXC chemokines has to be blocked rather than stimulated in cancer therapy. (Am J Pathol 2001, 159:1405–1414)

Chemokines have been associated with tumor biology for a long time. In fact, many chemokines have first been purified from tumor cells.1–5 The production of chemokines by tumor cells may be a paraneoplastic coincidence and either help the host to eliminate the tumor by immunosurveillance mechanisms6 or give an advantage to cancer progression. The latter is called the countercurrent principle of chemokine action and support the notion that paraneoplastic expression of ELR-positive CXC chemokines has to be blocked rather than stimulated in cancer therapy. (Am J Pathol 2001, 159:1405–1414)

Chemokine production by tumors is a well-known phenomenon, but its role in tumor biology remains debatable. Although intratumoral injection of granulocyte chemotactic protein-2 (GCP-2) had no effect on tumor parameters, needle-free stable expression of the chemokine resulted in enhanced tumor growth. It is shown here that tumors that express a potent form of GCP-2 induce a strong influx and activation of tumor-associated neutrophils. The production of GCP-2 leads to intratumoral expression of gelatinase B and advantage for tumor growth by increased angiogenesis. These results are in line with the countercurrent principle of chemokine action and support the notion that paraneoplastic expression of ELR-positive CXC chemokines has to be blocked rather than stimulated in cancer therapy. (Am J Pathol 2001, 159:1405–1414)

Chemokine production by tumors is a well-known phenomenon, but its role in tumor biology remains debatable. Although intratumoral injection of granulocyte chemotactic protein-2 (GCP-2) had no effect on tumor parameters, needle-free stable expression of the chemokine resulted in enhanced tumor growth. It is shown here that tumors that express a potent form of GCP-2 induce a strong influx and activation of tumor-associated neutrophils. The production of GCP-2 leads to intratumoral expression of gelatinase B and advantage for tumor growth by increased angiogenesis. These results are in line with the countercurrent principle of chemokine action and support the notion that paraneoplastic expression of ELR-positive CXC chemokines has to be blocked rather than stimulated in cancer therapy. (Am J Pathol 2001, 159:1405–1414)

Materials and Methods
Preparation and Purification of Recombinant Murine GCP-2

Mouse GCP-2 cDNA was cloned from MO murine fibroblasts.17 Confluent cell monolayers were obtained in Eagle’s Minimal Essential Medium (MEM) (Life Technologies, Gibco BRL, Paisley, Scotland) supplemented with 10% fetal calf serum (Life Technologies, Gibco BRL) and induced for 72 hours in medium containing 2% fetal calf serum supplemented with lipopolysaccharide (10 µg/ml)

Supported by the National Fund for Scientific Research (FWO-Vlaanderen), the Cancer Research Foundation of Fortis AB, the Belgian Federation against Cancer, and the Geconcerteerde Onderzoeksacties (GOA), Belgium.

A. W. is senior research assistant of the FWO-Vlaanderen.
Accepted for publication July 9, 2001.

Address reprint requests to Ghislain Opdenakker, Rega Institute, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: ghislain.opdenakker@rega.kuleuven.ac.be.

1405
plus double-stranded RNA poly(rI:rC) (50 μg/ml). Total RNA was extracted with the RNasy Mini Kit (Qiagen GmbH, Hilden, Germany) and quantified spectrophotometrically. One μg total RNA was reverse transcribed in 1× reverse transcriptase buffer (0.14 mol/L KCl, 8 mmol/L MgCl₂, 50 mmol/L Tris-HCl, pH 8.1), 25 mmol/L dithiothreitol, 0.15 mmol/L dNTPs (Amersham Pharmacia Biotech, Rainham, UK), 1 μg random hexamer primers (Life Technologies, Gibco BRL), 50 U human placental ribonuclease inhibitor and 4 U RAV-2 reverse transcriptase (both from Amersham Pharmacia Biotech) up to a final volume of 50 μl. The reverse transcriptase mixture was incubated for 80 minutes at 42°C, followed by denaturation of the enzyme for 5 minutes at 95°C. The subsequent polymerase chain reaction (PCR) was done on 2.5 μl of the reverse transcriptase mixture in a total volume of 50 μl, containing 1× ULTRA buffer (Applied Biosystems, Foster City, CA), 100 μmol/l dNTPs, 2 mmol/L MgCl₂, and 10 pmol of each primer. The two specific primers used were 5'-TACCATGGGCAAG-GAGCTGCGTTGTGTAGTGCC-3' (forward) and 5'-TACTCCAGTATATACAGGTTCTTTTGTGACTGGC-3' (backward) (respective Ncol and Xhol sites are in italics), amplifying a 210-bp cDNA fragment, encoding the full-size murine carbonic anhydrase (Mᵣ 18,400), lysozyme (Mᵣ 14,300), β-lactoglobulin (Mᵣ 18,400), lysozyme (Mᵣ 14,300), and bovine trypsin inhibitor (Mᵣ 6200). The fractions that contained the highest amount of ~6.5-kd protein on SDS-PAGE were dialyzed against 50 mmol/L formiate, 0.01% Tween 20, pH 4.0, and further purified by cation-exchange fast protein liquid chromatography. The purity and relative molecular masses of the proteins in the eluted fractions were determined by SDS-PAGE and silver-staining analysis. As a final purification step, fractions that contained the recombinant protein were purified by reverse phase-high pressure-liquid chromatography (HPLC) on a C-8 Aquapore RP-300 column. Proteins derived from reverse phase-HPLC were analyzed by mass spectrometry on an Esquire Electrospray ion trap mass spectrometer (Esquire, Bruker, Bremen, Germany) and analyzed for endotoxin contamination by the Limulus amebocyte lysate test (Bio-Whittaker, Walkersville, MD).

Intratumoral Injection of Bowes Melanoma Tumors with Recombinant Murine GCP-2(9-78)

Human Bowes melanoma cells (ATCC CRL 9607) were cultured in Eagle's MEM supplemented with 10% fetal calf serum. Confluent monolayers were trypsinized, cells were washed twice with MEM and resuspended at a concentration of 2.5 × 10⁷ cells/ml. Eight-week-old female athymic nu/nu mice (NMRI background) were injected intradermally with 5 × 10⁶ melanoma cells suspended in 200 μl of MEM. On day 3 and every Monday, Wednesday, and Friday onwards, animals were injected at the tumor site with 20 μl of sample, containing 500 ng of recombinant murine GCP-2(9-78) (prepared and purified as described above) diluted in 0.25% human serum albumin (endotoxin ≤ 0.1 ng/ml) (Sigma, St. Louis, MO) in saline (endotoxin-free 0.9% NaCl) (Baxter, Leszines, Belgium). The dosage of 500 ng per injection site was derived from published data with other chemokines, preclinical experiments with various dosages of GCP-2 and calculation of in vivo obtainable levels in small-sized tumors. The latter were calculated from data on in vitro cellular GCP-2 production yields. In the control mice, the tumors were injected with diluent. All animals were observed twice a week and tumor size was estimated (in square millimeters) using the formula 3.14 × (a × b)/4, with a as the largest diameter and b as the smaller diameter.

Mammalian Expression Vector Construction

A 399-bp cDNA fragment, encoding the full-size murine GCP-2 protein [signal peptide (40 AA) + mature protein (92 AA) + stop codon], was amplified by PCR from cDNA of lipopolysaccharide-stimulated MO murine fibroblasts, prepared as described above. The murine GCP-2-specific primers used were 5'-TACCTCGAGATGAGCCCTCAGGCTCCAGGCTCC-3' (forward) and 5'-TACCTCTGATGAGCCCTCAGGCTCC-3' (backward) (Xhol site is in italics). The specific PCR product was gel-purified, digested with Xhol, and cloned into the corresponding site of the pLXIN vector (Clontech Laboratories, Palo Alto, CA). Verification of the sequences of the sense (pLXIN-mGCP-2) and antisense (pLXIN-mGCP-2-REV) was done by the dideoxynucleotide chain termination method as described above.

Transfection of Bowes Melanoma Cells and Selection of Transfected Cell Lines

Aliquots of 20 μg of the constructs pLXIN-mGCP-2 and pLXIN-mGCP-2-REV were linearized with AccI (Roche Diagnostics GmbH, Mannheim, Germany) and gel-purified. One day before transfection, confluent monolayers
of human Bowes melanoma cells, grown in Eagle’s MEM supplemented with 10% fetal calf serum, were plated in 24-well dishes at a density of $5 \times 10^4$ cells/well. Cells were transfected with (1, 2, or 3) $\mu$l Fugene6 (Roche Diagnostics, GmbH) in combination with the linearized plasmid DNA (300, 600, or 900 ng). The procedure was performed as described by the manufacturer. Three days after transfection, cells were grown in the presence of 1 mg/ml G418 (Life Technologies, Gibco BRL). G418-resistant colonies were isolated and expanded. To verify whether the cell lines expressed human chemokines, subclones were tested by specific enzyme-linked immunosorbent assay (ELISA) for the expression of human IL-8 and human GCP-2. For the human GCP-2 sandwich ELISA, microtiter plates were coated with 0.2 $\mu$g/ml of polyclonal anti-human GCP-2 antibody (PeproTech, Rocky Hill, NJ) and the antigen was captured with 0.25 $\mu$g/ml monoclonal anti-human GCP-2 antibody (R&D Systems, Abingdon, UK).

**Analysis of Murine GCP-2 Expression by Northern and Western Blot**

To analyze the murine GCP-2 mRNA (sense or antisense) levels of the individual transfected cell lines, monolayers of parental Bowes cells and transfectants were grown to confluency and total RNA was prepared with the use of the RNeasy Mini Kit (Qiagen). Samples of 10 $\mu$g of RNA were separated on a formaldehyde/agarose gel and blotted onto a nylon membrane. The membrane was hybridized with a murine GCP-2 probe (399-bp cDNA fragment, excised with XhoI from pLXIN-mGCP-2) using the ExpressHyb hybridization solution (Clontech Laboratories) at the highest stringency. Probe labeling was by random priming in the presence of [a-32P]dCTP (Amersham Pharmacia Biotech). Control of sample preparation and handling was done by ethidium bromide staining of the RNA after electrophoresis in the agarose gel. To test the GCP-2 protein expression by the individual Bowes melanoma cell subclones, cells were grown to confluency and the growth medium was replaced by medium without serum. The cell culture supernatants were collected 24 hours later and subjected to Western blot analysis. Supernatants (7.5 $\mu$l) were loaded on a 16.5-Tris-tricine Ready Gel (Bio-Rad, Hercules, CA) and subjected to SDS-PAGE. As a positive control, purified natural murine GCP-2 was loaded. Proteins were transferred to a polyvinylidene difluoride membrane by electroblotting and the blot was blocked in 2% casein in NT-buffer (10 mmol/L Tris-HCl, pH 7.4, 100 mmol/L NaCl). After three wash steps in wash buffer (NT-buffer and 0.1% Tween-20), the blot was incubated for 2 hours with 1 $\mu$g of biotinylated anti-mouse LIX/GCP-2 antibody (R&D Systems) diluted in 5 ml of wash buffer and 0.1% casein. The blot was washed three times for 5 minutes and subsequently incubated for 1 hour with streptavidin-horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA) at a 1:10,000 dilution in wash buffer and 0.1% casein. The blot was again washed (five times for 5 minutes) and protein was visualized after incubation of the blot in enhanced chemiluminescence solution according to the protocol of the manufacturer (Amersham Pharmacia Biotech), and exposure to a BioMax MR-2 film (Kodak, Rochester, NY).

**Injection of Stably Transfected Melanoma Cell Lines in nu/nu Mice and Histology**

The in vivo study protocols were approved by the local ethical committee (National certification LA1210243, Belgium). Eight-week-old female athymic nu/nu mice (NMRI background) were injected intradermally at the left abdominal side with 2 $\times$ 10^6 or 5 $\times$ 10^6 exponentially growing parental or transfected human Bowes melanoma cells resuspended in 200 $\mu$l of MEM. Tumor diameters were measured once a week and the size was calculated as described above. For histological analysis, from each group of animals (parental, antisense, and sense transfectants) and from both developmental stages of the tumor (early tumors, late tumors) mice were killed and analyzed individually in two independent experiments. Biopsies from the primary tumor, brain, lung, and intercostal tissue were excised and fixed in Bouin’s fixative. Standard paraffin embedding, sectioning, and staining with hematoxylin and eosin (H&E) were performed for microscopic examination. S-100 staining for melanoma tumors was performed to analyze the presence of tumor metastases in different organs. To distinguish infiltrated neutrophils from tumor cells, paraffin-embedded sections of the tumors were subjected to myeloperoxidase (MPO) staining. Neutrophils were counted in 20 fields (magnification of x400) of nonnecrotic tumor tissue in end-stage (9 weeks) or early (9 days) tumors. Results, scored by two independent researchers for whom the tumor sample labels were covered, were expressed as the mean ± SEM. Tumor tissue was also frozen at –70°C and frozen sections were immunostained for CD31 using the MEC 13.3 anti-CD31 monoclonal antibody (BD Pharmingen, San Diego, CA).

**Preparation of Tumor Extracts and Analysis**

Tumor tissue was homogenized in 9 volumes of phosphate-buffered saline and Complete (1 tablet/50 ml buffer) (Roche Diagnostics, GmbH) and cell debris was removed by centrifugation. Total protein content was determined by Bradford analysis using bovine serum albumin as a standard protein. Murine GCP-2 was detected with a sandwich ELISA, using recombinant murine GCP-2(9-78) as a standard. In this test, coating of the plate was done with 1 $\mu$g/ml of anti-mouse LIX/GCP-2 antibody (R&D Systems) and capturing of the antigen was with 0.1 $\mu$g/ml of biotinylated anti-mouse LIX/GCP-2 antibody (R&D Systems). The detection limit for the muGCP-2 ELISA was 0.1 ng/ml. Gelatinase B/MMP9 activity in the tumor extracts was determined by SDS-PAGE gelatin zymography as described previously.
Results

Expression and Purification of Recombinant Murine GCP-2(9-78)

Because it had been shown previously\(^2^3\) that the amino- and carboxy-terminally truncated natural isoform GCP-2(9-78) is more potent than intact murine GCP-2(1-92), the recombinant GCP-2(9-78) form was expressed in *E. coli* and purified to homogeneity. Recombinant mouse GCP-2(9-78) possessed the expected size (\(\sim 6.2\) kd on SDS-PAGE; \(\sim 6.8\) d by electrospray mass spectrometry) and was resuspended in saline at a concentration of \(100 \mu g/ml\) (Figure 1). This preparation possessed *in vitro* neutrophil chemotactic activity and its endotoxin level was \(<25\) pg/ml.

Local Injection of Recombinant Murine GCP-2(9-78) Has No Effect on Tumor Growth

The influence of murine GCP-2(9-78) on the growth of human Bowes melanoma cells *in vivo* was evaluated by intratumoral injection. Nude mice were subcutaneously xenografted with \(5 \times 10^6\) Bowes melanoma cells at the abdominal side. From day 3 onwards (when small tumors appeared) and for a period of 3 weeks, 500 ng of recombinant murine GCP-2(9-78) or diluent alone (control) was administered three times a week into the tumor. Tumor diameters were monitored and the tumor size was calculated. Pooled data (means and standard errors of the mean) from two independent experiments, in which each group consisted of 10 animals, are shown.

Mouse GCP-2 Gene Transfer Enhances the Development of Bowes Melanoma Tumors

Sense and antisense transfectants of the murine GCP-2 cDNA in Bowes melanoma cells were generated. To test the mRNA production levels in the individual transfected subclones, Northern blot analysis was performed (Figure 3A). Total RNA of the parental melanoma cells was used as a negative control. Several clones, which produced relatively high levels of sense or antisense muGCP-2 mRNA were selected and further tested for the production of muGCP-2 protein by Western blot analysis (Figure 3B). The Western blot analysis showed the presence of multiple bands that co-migrated with those present in the

---

**Figure 1.** Biochemical characterization of recombinant muGCP-2(9-78). A: The silver-stained SDS-PAGE gel of reverse phase-HPLC-purified recombinant muGCP-2(9-78). The sample (S) is compared with a mixture of protein standards (M) of which the molecular sizes are indicated on the left in kd. Different fractions of reverse phase-HPLC purified recombinant muGCP-2(9-78) were subjected to electrospray mass spectrometry analysis. The unprocessed (B) and charge-deconvoluted (C) spectra are shown. Fractions containing pure \(7626.8\) d muGCP-2(9-78) were pooled and used for further studies.

**Figure 2.** Intratumoral administration of murine GCP-2 in melanoma tumors. Parental human Bowes melanoma cells \((5 \times 10^6)\) were inoculated subcutaneously into the left abdominal side in nude mice. From 2 days after inoculation onwards, 500 ng of recombinant murine GCP-2(9-78) or diluent alone (control) was administered three times a week into the tumor. Tumor diameters were monitored and the tumor size was calculated. Pooled data (means and standard errors of the mean) from two independent experiments, in which each group consisted of 10 animals, are shown.
supernatants were collected and 7.5–medium was replaced with serum-free medium. After 24 hours, cell culture Bowes melanoma cells were grown to confluency. Consecutively, the growth
3, C K/H11001 clones GB B: protein expression.
electrophoresis. The 28S and 18S ribosomal RNAs are indicated on the figure.

Figure 3. mRNA and protein levels of murine GCP-2 in Bowes melanoma transfectant cell lines. A: Northern blot analysis. Bowes melanoma cell clones with sense (A+, B+, C+, F+, H+, K+, L+, O+, Q+, GB+1, GB+2, GB+3, GB+4, GB+5, GB+6, D+, G+, I+, J+, M+, N+, P+, R+) or antisense (E−, GB-7, GB-8) muGCP-2 constructs and parental Bowes melanoma cells were tested for specific mRNA levels. Total RNA was extracted, purified, and equivalent amounts of 10 μg were subjected to Northern blot analysis. The membrane was hybridized with a muGCP-2-specific probe and the film was exposed overnight. Size-standardization and analysis of the loading of equal membrane was hybridized with a muGCP-2-specific probe and the film was exposed overnight. Size-standardization and analysis of the loading of equal

Figure 4C. Obviously, not only the size of the sense (GB+3) tumors differed from that of the parental and antisense (GB-8) controls, but also the GB+3 tumors had a dark bluish color that was not observed in the others.

natural mouse GCP-2. These bands correspond to the various truncation variants by amino- and carboxyterminal processing, as previously described.23 The subclones GB+3 (sense, based on protein expression) and

GB-8 (antisense) were selected and expanded for further in vivo studies. At several time intervals, throughout a period of more than 12 months, the supernatants were tested for murine GCP-2 production to provide evidence that the expression was constitutive and stable. The subclones (with a human cell line origin) were also tested for human IL-8 and human GCP-2 expression by specific ELISAs and scored negative in both tests (data not shown).

The effects of muGCP-2 sense and antisense gene transfection in the subclones were assessed and compared with those of parental (untransfected) Bowes melanoma cells. In several independent experiments, nude mice were subcutaneously injected with the various tumor cell lines and tumor growth was monitored. From week 8 onwards, the tumor sizes of the GB+3 tumors were clearly larger than those of GB-8 (antisense control) and parental Bowes tumors (Figure 4, A and B). To assess whether the increase in tumor size was caused by a direct effect of muGCP-2 on tumor cell growth, the in vitro proliferation of Bowes melanoma cells was determined in the presence of recombinant murine GCP-2(9-78). Murine GCP-2(9-78) (50 ng/ml) was added to Bowes melanoma cells and cell numbers were determined after 3 days. Murine GCP-2 did not have an influence on the in vitro proliferation rate of the tumor cell lines GB+3, GB-8, and parental Bowes cells (data not shown).

All tumors (Figure 4A) were photographed at week 8 and a representative tumor of each group is shown in Figure 4C. Obviously, not only the size of the sense (GB+3) tumors differed from that of the parental and antisense (GB-8) controls, but also the GB+3 tumors had a dark bluish color that was not observed in the others.

In Vivo Neutrophil Chemotaxis and Activation
At the end of the experiment (9 weeks), the animals were autopsied. Macroscopically, the structures of the GB+3 tumors were totally different from the controls. Tumors of GB-8 and parental Bowes melanoma cells were solid and easy to distinguish from the surrounding tissue, whereas the GB+3 tumors were soft, bloody, and connected with the underlying tissue. Different organs (lung, brain, intercostal tissue, and liver) were inspected but macroscopically no differences were observed between controls (GB-8 and parental) and GB+3 tumors. Biopsies of the primary tumors, the brains, lungs, and intercostal tissues, were histologically analyzed. Staining for S-100 protein showed microscopic lung metastases of the melanomas in all three animal groups, whereas the other studied tissues were not affected (data not shown). In the three tumor groups, necrotic regions were reproducibly found and distinguished from nonnecrotic tissue. Figure 5 (left) represents tumor tissue of parental, GB-8 and GB+3 tumors after H&E staining. By staining for MPO, we observed a neutrophil load in the necrotic regions of the tumor that was 7 to 10 times higher in the GB+3 compared to the GB-8 or parental tumors (Figure 5, right, and Figure 6A). In necrotic regions, many neu-
trophils were present in all of the parental, GB-8, and GB/H3 tumors. Individual tumors of each group, obtained from independent experiments, were dissected, and frozen at −70°C for further freeze-section analysis. Tumor extracts were tested for the presence of mouse GCP-2 with the use of a specific ELISA. In GB+3 tumor tissue, a level of ~25 ng muGCP-2 per mg total protein was detected, which was two to three times higher than in the controls (GB-8 and parental) tumors. This result, together with the finding of 7 to 10 times more polymorphonuclear cells in the nonnecrotic tumor tissue shows that the GB+3 transfected Bowes melanoma tumor cells stably produce active muGCP-2 protein.

Tumor Angiogenesis in Vivo by Mouse GCP-2

To determine whether tumor angiogenesis is a mechanism by which muGCP-2 influenced Bowes melanoma growth, the vascularity was assessed by immunohistochemistry with CD31-specific antibodies on sections of frozen tissues from 9-week-old tumors. No significant differences in the numbers of cells staining positive for CD31 in the three types of late-stage tumors were detected. Similarly, no differences were observed when the numbers of vessel transections were counted per microscopic field (data not shown). To exclude that the angiogenic effects of GCP-2 gene transfer in late stage tumors were faded out by the necrosis and endogenous mouse chemokine production, we also assessed growing tumors at an early stage before necrosis was evident. Nude mice were subcutaneously injected with 5 × 10⁶ parental or muGCP-2 transfected sense (GB+3) or antisense (GB-8) Bowes melanoma cells. After 9 days, tumor tissue was dissected and freeze-sections were prepared. After MPO staining, the neutrophil load in the GB+3 tumor was 7 to 10 times higher than in the control tumors, which is in agreement with the neutrophil load of nonnecrotic regions of tumors at 9 weeks. Gelatinase B activity in such tumor extracts was determined by SDS-PAGE zymography (Figure 6B), and in the GB+3 (sense) tumors, found to be at least three times higher than in the GB-8 and parental tumors. This is in agreement with the finding that in GB+3 tumors many more neutrophils are present, and indicates that the in vivo chemotaxis was accompanied by neutrophil activation.

Histopathology of tumors at a late stage (9 weeks) indicated a considerable neutrophil influx in the GCP-2-producing tumors (see Figure 5, MPO-staining) and, macroscopically, these tumors were larger, shining bluish through the skin and, when dissected, contained hemorrhagic pus. Lacunar vessel growth was evidenced by the softness and the fact that the red and white blood cells leaked out of the GCP-2 transfected tumors, whereas in the antisense-transfected and parental tumors, this was not observed. To show these elements by histopathology, we also dissected tumors at an early stage (day 9). Figure 7 illustrates the growth characteristics of these tumors as well as the microscopic peritumoral angiogenesis in the GCP-2 sense transfectant GB+3. In parental and GCP-2 antisense-transfected tu-
mers, the solid tumors were confined and some CD31-positive vessels were observed, mainly in coexistence with normal tissue at the tumor front. As a contrast, in the GCP-2-producing tumors (GB+3) an extensive vascularization was observed at the tumor periphery. These vessels were not penetrating into the tumor. Furthermore, within the GB+3 neoplastic tissue, there was, already at this early stage, evidence of necrosis mainly at the center. When we counted the CD31-positive vessels (per microscopic field) within the tumors, no significant differences were found between the parental, sense, and antisense groups (data not shown). At the tumor perimeter the vessel growth was significantly stimulated by GCP-2 expression (Figure 7). In conclusion, tumor-derived GCP-2 induced peritumoral angiogenesis in vivo and assisted in tumor progression.

Figure 5. Histological analysis of murine GCP-2-transfected tumors. **Left:** H&E staining of parental, GB-8, and GB+3 tumors in vivo. **Right:** MPO staining of similar paraffin-embedded sections. Scale bars, ~50 μm.
Discussion

Many tumors produce chemokines, which may explain the presence of tumor-associated leukocytes. However, the role of these chemokines in tumor biology is not clear. They may assist in immunosurveillance and help to eliminate the tumor. Alternatively, they may help the tumor for its growth and invasion. We coined the latter "the countercurrent principle" and recently reviewed three key elements in this model: invasion promotion by enhancing the protease load of the tumor, tumor growth promotion by provision of trophic factors, and angiogenesis. The control of angiogenesis has been defined as an important function of chemokines. Recently, it has also been shown that the expression of IL-8 regulates angiogenesis and induces metastasis of specific tumors.

By using gene transfer technology, we here provide in vivo proof that a solid tumor indeed may have an advantage by producing a chemokine. For this, a tumor model of human melanoma cells that were xenotransplanted in nude mice was used. Evaluating the role of GCP-2 by intratumoral injection of the recombinant protein, we did not observe any significant effect on tumor parameters including tumor growth and survival of the host (data not shown). To evaluate the long-term effects in a needle-free setting and to study whether the tumor itself may acquire an advantage by the production of a chemokine, we stably transfected the murine GCP-2 cDNA into a melanoma cell line and compared various parameters in vivo. These included GCP-2 expression, tumor growth, neutrophil chemotaxis, gelatinase B degranulation from neutrophils, in vivo metastasis to the lungs, and tumor angiogenesis. Evidence of the countercurrent principle was found by the observation that GCP-2 expressing tumors, already at an early stage, had a higher neutrophil influx and showed a significantly increased angiogenesis. This angiogenesis was peritumoral allowing for a larger tumor size and a hemangioma-like macroscopic appearance to develop.

To investigate if this resulted in an elevated protease load, tumor extracts were subjected to zymography. No significant differences in gelatinase B levels were detected in extracts of large end-stage tumors with large necrotic areas, when compared with parental Bowes melanoma tumors and antisense transfected tumors (data not shown). This may be the result of the strong inflammatory component. In line with this, we observed areas of necrosis in the late-stage tumors with parental, sense- and antisense-transfected Bowes cells. Microscopically, these necrotic tumor areas contained in all instances pus. In the early developmental stages of the tumor, however, significantly higher levels of gelatinase B were observed in GCP-2-expressing tumors.

Obviously, in this model the vasculature remained peritumoral, which may imply that the high GCP-2 expression levels (chemokines follow a bell-shaped dose-response effect) prohibited vessel growth or that other factors play a role at the tumor front to allow or prohibit the blood vessels to grow into the tumor. Therefore, the model with GB +3 melanoma cells may also become useful to define and study molecules that allow the blood vessels to grow into the tumor or substances that inhibit the GCP-2-induced angiogenesis. The angiogenic effect of ELR-positive CXC chemokines has been established in inflammation and obviously also plays a role in tumor biology. This example of neutrophil chemotaxis and activation to release gelatinase B into the tumor site places the recent studies of potentiation of CXC che-
mokines by gelatinase B also central in tumor biology. The role played by neutrophils may be studied by neutrophil depletion, the latter of which also occurs in patients under chemotherapy. However, we tried to gain insights in the natural tumor evolution without leukocyte depletion. Further studies with syngeneic tumor models may be better to evaluate the roles played by various leukocyte types.

Studies on skin carcinogenesis also show evidence for the countercurrent model and the contribution of leukocytes, as well as gelatinase B, in tumor progression. In addition, MGSA/GRO proteins (CXCL1 and CXCL3) with melanocyte growth-promoting activity also lead to tumor angiogenesis. Chemokines, chemotactically leukocytes, as well as induced metalloproteinases, are to be considered as important players in

Figure 7. GCP-2 gene transfection induces peritumoral angiogenesis in vivo. Tumor samples were collected at 9 days after inoculation of $5 \times 10^6$ cells and processed as frozen sections. These were stained for mouse CD31 as a marker for endothelial cells. The left column shows low-power magnification of parental, antisense GB-8, and sense GB+3 transfectants at the front of the tumors with the normal tissue. CD31-positive cells are stained in red. The right column shows similar pictures of other sections at a higher magnification to visualize in more detail the peritumoral network of vessels formed in the GCP-2-expressing tumor variant GB+3. Scale bars, ~50 μm. The peritumoral vessel transection counts per microscopic field (original magnification, ¥400) in this specific experiment were 16.6 ± 1.7 for GB+3, 1.8 ± 0.2 for GB-8, and 2.8 ± 0.6 for the parental Bowes cells (means ± standard errors, $n = 5$).
the control of tumor vessel growth, side of other
well-known (lymph)angiogenic and angiostatic factors
in tumor biology.  

Acknowledgments

We thank P. Fiten for DNA sequence analysis and image
analysis, Brigitte Maes for light microscopy and photog-
raphy, and P. Proost for mass spectrometry analysis.

References

1. Bottazzi B, Polentarutti N, Acera N, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A: Regulation of the macrophage content of
2. Graves DT, Jiang YL, Williamson MJ, Valente AJ: Identification of
monocyte chemotactic activity produced by malignant cells. Science
1989, 245:1490–1493
3. Bottazzi B, Colotta F, Sica A, Nobili N, Mantovani A: A chemotrac-
tant expressed in human sarcoma cells (tumor-derived chemotactic factor, TDCF) is identical to monocyte chemotactant protein-1
monocyte chemotactant and activating factor (MCP-1/MCAF). Int J
Cancer 1990, 45:795–797
NH2-terminal sequence-characterized human monokine possessing
neutrophil chemotactic, skin-reactive, and granulocytosis-promoting
5. Van Damme J, Proost P, Lenaerts JP, Opdenakker G: Structural and
functional identification of two human, tumor-derived monocyte che-
motactic proteins (MCP-2 and MCP-3) belonging to the chemokine
6. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and
function of tumor-associated macrophages. Immunol Today 1992,
13:265–270
7. Opdenakker G, Van Damme J: Chemotactic factors, passive invasion
8. Opdenakker G, Van Damme J: Novel monocyte chemotactants in
cancer. Chemokines and Cancer. Edited by BJ Rollins. Totawa, Hu-
Elner VM, Strieter RM: Interleukin-8 as a macrophage-derived medi-
10. Zlotnik A, Yoshie O: Chemokines: a new classification system and
their role in immunity. Immunity 2000, 12:121–127
11. Clark-Lewis I, Dewald B, Geiser T, Moser B, Mantovani A: A chemoat-
factor 4 binds to interleukin 8 receptors and activates neutrophils
when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci
USA 1993, 90:3574–3577
12. Hebert CA, Vintarcik RV, Baker JB: Scanning mutagenesis of inter-
leukin-8 identifies a cluster of residues required for receptor binding.
13. Bagnoli M, Dewald B, Moser B: Interleukin-8 and related che-
motactic cytokines-CXC and CC chemokines. Adv Immunol 1994, 55:
97–179
chemokines as regulators of angiogenesis. Shock 1996, 4:155–160
role of the ELR motif in CXC chemokine-mediated angiogenesis.
protein (GCP-2) from human tumor cells. In vitro and in vivo compar-
ison with natural forms of GRO, IP-10, and IL-8. J Immunol 1993,
150:1000–1010
G, Van Damme J: Identification of mouse granulocyte chemotactic
protein-2 from fibroblasts and epithelial cells. Functional comparison
1996, 157:1736–1743
genes encode intercellular mediators, including a new C-X-C chemo-
19. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P,
Winter G: Multi-subunit proteins on the surface of filamentous phage:
methodologies for displaying antibody (Fab) heavy and light chains.
20. Van Coillie E, Proost P, Van Aelst I, Struyf S, Polfliet M, De Meester I,
Harvey DJ, Van Damme J, Opdenakker G: Functional comparison of
two human monocyte chemotactic protein-2 isoforms, role of the
aminoterminal pyroglutamic acid and processing by CD26/dipeptidyl
21. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
cells produce an 85 kDa gelatinase regulated by phorbol 12-myris-
23. Wuyts A, D’Haese A, Cremers V, Menten P, Lenaerts JP, De Loof A,
Hermans H, Proost P, Van Damme J: NH2- and COOH-terminal
truncations of murine granulocyte chemotactic protein-2 augment the
in vitro and in vivo neutrophil chemotactic potency. J Immunol 1999,
163:6155–6163
24. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehret JE, Burdick
MD, Strieter RM: CXC chemokines in angiogenesis. J Leukoc Biol
2000, 68:1–8
Bar-Eli M, Radinsky R, Pettawy CA, Dinney CP: Interleukin 8 expres-
sion regulates tumorigenicity and metastases in androgen-indepen-
R, Dinney CP: Interleukin 8 expression regulates tumorigenicity and
27. Van Den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G:
Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterm-
inal processing, whereas it degrades CTAP-III, PF-4, and GRO-
2681
bone-marrow-derived cells contributes to skin carcinogenesis. Cell
2000, 103:481–490
29. Haighnegahdar H, Du J, Wang DZ, Strieter RM, Burdick MD, Nannay
LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A: The tumor-
igenic and angiogenic effects of MGSA/GRO proteins in melanoma.
30. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?
Lancet 2001, 357:539–545
31. Hanahan D, Folkman J: Patterns and emerging mechanisms of the
32. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn
E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous in-
33. Stackler SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo
M, Jackson DG, Nishikawa S-I, Kubo H, Achen MG: VEGF-D pro-
motes the metastatic spread of tumor cells via the lymphatics. Nat
34. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P,
Riccardi L, Altasio K, Claffey K, Detmar M: Induction of tumor angiog-
genesis by VEGF-C promotes breast cancer metastasis. Nat Med